News

“Hopeful times” anticipated by leading MS advocate upon approval of MS treatment
28.04.2013

“Hopeful times” anticipated by leading MS advocate upon approval of MS treatment

The European Commission has granted marketing authorization for Aubagio 14 mg (teriflunomide), an oral therapy recommended for the treatment of…

“Hopeful times” anticipated by leading MS advocate upon approval of MS treatment

28.04.2013

The European Commission has granted marketing authorization for Aubagio 14 mg (teriflunomide), an oral therapy recommended for the treatment of…

The Written Declaration bid for neurodegenerative diseases: a useful experience

28.03.2013

The bid for a Written Declaration for neurodegenerative diseases (NDDs) in the workplace managed to gather 161 signatures from Members…

28.03.2013

The Written Declaration bid for neurodegenerative diseases: a useful experience

The bid for a Written Declaration for neurodegenerative diseases (NDDs) in the workplace managed to gather 161 signatures from Members…

1 15 16 17